MedTrace Logo

Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People

NCT04781400 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 536

Last updated 2022-08-17

No results posted yet for this study

Summary

Sub Saharan Africa is home to only 12% of the population, but accounts for approximately 70% of the global burden of HIV infection and 84% of infections among young people aged 10-24 years. South Africa, which currently has the largest SARS-CoV-2 pandemic in SSA, also has the largest HIV epidemic globally. Access and service delivery barriers to engaging in HIV care have contributed to estimates that only 49% of adolescents (aged 10-19 years) entering care from 2005-2016 have initiated antiretroviral therapy (ART). In response to the SARS-CoV-2 pandemic the South African government has implemented national lock-down orders that we predict will further inhibit treatment engagement among young people. Research is needed to identify best practices for safely retaining young people living with HIV (YPLWH) in care during COVID-19.

Conditions

  • HIV Infections
  • Covid19
  • Health Care Utilization
  • Gender-based Violence

Interventions

BEHAVIORAL

Mobile phone support

Mobile phone support (SMS)

BEHAVIORAL

Remote service delivery model

ART treatment delivery via a courier service

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Karolinska Institutet

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • University of KwaZulu

    collaborator OTHER

  • Desmond Tutu HIV Foundation

    lead OTHER

Principal Investigators

  • Linda-Gail Bekker · Desmond Tutu HIV Foundation

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2022-05-13
Completion
2022-05-13

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04781400 on ClinicalTrials.gov